#None #AI #Appian #PSI CRO

Appian and PSI CRO Form Strategic Partnership to Enhance Clinical Trials

In a landmark partnership aimed at revolutionizing clinical trial operations, Appian and PSI CRO have formally announced the successful launch of their first joint AI-driven process orchestration solution. This new technology is set to enhance the efficiency of clinical trial site identification and selection across various therapeutic areas and geographical regions.

Clinical trials are complex endeavors often involving extensive coordination among multiple stakeholders. These processes can be cumbersome, requiring immense documentation and multiple parallel activities across different locations. The introduction of the AI-powered process orchestration solution marks a significant shift from previously manual and decentralized methods to a streamlined digital format. This innovative solution not only automates the site selection process but also offers comprehensive oversight throughout the entire clinical trial lifecycle.

Recognized by Gartner as a leader in the 2026 Magic Quadrant for Business Orchestration and Automation Technologies, Appian’s platform is a pivotal component in this initiative. It empowers the identification and selection of study sites, delivering improved visibility and expedited execution. By orchestrating the end-to-end process, the new solution connects people, data, systems, and AI within a single cohesive workflow, which enhances collaboration and document processing.

As highlighted by industry experts, the integration of AI and automation into clinical trial operations is crucial for improving both the speed and success rate of studies. The joint venture aims to ensure that clinical trials are not only completed on time but also with greater accuracy, providing a scalable model that can reduce delays in patient enrollment and eliminate non-enrolling sites.

Kirill Soldatov, Head of Process Improvement at PSI, expressed confidence in the partnership's potential: “We are rethinking our operational processes to create a more connected model that leverages automation and AI capabilities. This national site selection initiative is a foundational step toward that vision.”

Following the launch of this initial solution, Appian and PSI plan to assess further use cases that apply AI-driven process orchestration throughout the clinical trial lifecycle, emphasizing an overarching goal to decrease clinical study durations and enhance predictability. This innovation not only promises to shorten timelines for bringing new medical products to market but also has the potential to lower costs for consumers considerably.

With both companies committed to innovation and progressive operational models, the future of clinical trials looks poised for a transformation. As we observe the advancements in AI and process orchestration, it's evident that the future of clinical research is heading toward a more efficient and effective direction that ultimately serves patients better.

For life sciences companies interested in leveraging AI to expedite their market entry, this groundbreaking partnership illustrates the significant impact that technology can have on clinical development phases. As Appian and PSI CRO build on this foundation, the implications for faster, more reliable clinical trials could reshape the healthcare landscape as we know it today.